Signalling networks in prostate cancer

Poster Session 20

  • Location:
    Room Vienna (Hall B2, level 0)
  • Chairs:
     H.G. Lilja, New York (US)
     G. Jenster, Rotterdam (NL)
     S. Perner, Bonn (DE)
  • Aims and objectives of this session

    Novel oncogenic and tumour suppressive miRNA have been discovered in prostate cancer. Recent studies focused on identification of their targets and regulation of cellular events. In this session, signaling pathways regulated by miRNA and androgen receptors in cancerous prostate will be discussed.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
MiR-130a modulates high-fat diet-induced tumour progression through the activation of MET in prostate cancer

By: Narita S.1, Matsuda Y.1, Nara T.1, Huang M.1, Yoshioka T.2, Takayama K.1, Numakura K.1, Tsuruta H.1, Maeno A.1, Saito M.1, Inoue T.1, Satoh S.3, Habuchi T.1

Institutes: 1Akita University School of Medicine, Dept. of Urology, Aktia, Japan, 2Akita University School of Medicine, Dept. of Molecular Pathology and Tumor Pathology, Aktia, Japan, 3Akita University Hospital, Dept. of Center For Kidney Disease and Transplantation, Aktia, Japan

MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer

By: Takahara K., Inamoto T., Ibuki N., Uchimoto T., Saito K., Takai T., Tanda N., Hirano H., Nomi H., Kiyama S., Azuma H.

Institutes: Osaka Medical College, Dept. of Urology, Takatsuki, Japan

The castration-resistant prostate cancer-associated miRNAs, miR-3687 and miR-4417, are involved in tumour cell hypoxia response and tumour cell migration

By: Fussek S.1, Rönnau C.2, Span P.N.3, Burchardt M.2, Verhaegh G.W.1, Schalken J.A.1

Institutes: 1Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 2University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, 3Radboud University Medical Center, Dept. of Radiation Oncology, Nijmegen, The Netherlands

MicroRNA-660 is down-regulated in prostate cancer and directly regulates prostate-specific membrane antigen

By: Erdmann K., Bienert F., Füssel S., Wirth M.

Institutes: TU Dresden, Dept. of Urology, Dresden, Germany

Up-regulation of androgen receptor expression in enzalutamide-resistant prostate cancer cells

By: Höfer J., Akbor M., Ofer P., Culig Z., Klocker H., Heidegger I.M.

Institutes: Medizinische Universität Innsbruck, Dept. of Urology, Innsbruck, Austria

Cell surface branching glycan regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling

By: Tobisawa Y.1, Mikami J.1, Yoneyama T.1, Hatakeyama S.1, Mori K.1, Hashimoto Y.1, Koie T.1, Ohyama C.1, Fukuda M.2

Institutes: 1Hirosaki University, Dept. Of Urology, Hirosaki, Japan, 2Sanford Burnham Prebys Medical Discovery Institute, Tumour Microenvironment and Metastasis Program, NCI-Designated Cancer Center, La Jolla, United States of America

Role of anti-metastatic laminin-binding O-glycan on α-dystroglycan regulated by miR-X in prostate cancer

By: Yoneyama T.1, Fujita N.2, Imamura H.2, Okamoto A.2, Yamamoto H.2, Mori K.2, Hatakeyama S.2, Hashimoto Y.1, Koie T.2, Tobisawa Y.2, Fukuda M.3, Ohyama C.2

Institutes: 1Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplantation & Regenerative Medicine, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Sanford-Burnham Prebys Medical Discovery Institute, Dept. of Tumor Microenvironment Program, La Jolla, United States of America

Down-regulation of CDKN3 inhibited prostate cancer proliferation in vitro and in vivo via regulating cell cycle and DNA replication signaling

By: Yiping Z., Dingwei Y., Hailiang Z., Bo D.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shang Hai, China

Characterisation of immune infiltrates in malignant and benign prostate tissues

By: Woon D.T.S.1, Whitty G.2, Saxena M.2, Bolton D.1, Davis I.2

Institutes: 1Austin Health, Dept. of Urology, Melbourne, Australia, 2Ludwig Institute For Cancer Research, Dept. of Uro-Oncology Laboratory, Melbourne, Australia

Induction of prostate-specific membrane antigen expression (PSMA) expression and internalization of anti-PSMA monoclonal antibodies in human endothelial cells

By: Nguyen T.P.D., Xiong P., Pan S., Liu H., Guo M., Leconet W., Navarro V., Kim S., Bander N.

Institutes: Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America

The α1-adrenoceptor antagonist prazosin, but not tamsulosin, suppresses hypoxia inducible factor-1α and radio-sensitises hypoxic prostate cancer cells

By: Forbes A.1, Mc Dermott C.1, Anoopkumar-Dukie S.2, Christie D.3, Chess-Williams R.1

Institutes: 1Bond University, Dept. of Urology Research, Gold Coast, Australia, 2Griffith University, School of Pharmacy, Gold Coast, Australia, 3Genesis CancerCare, Dept. of Radiation Oncology, Gold Coast, Australia

PD-L1 expression in prostate cancer

By: Hashimoto Y., Iwamura H., Imai A., Hatakeyama S., Yoneyama T., Koie T., Ohyama C.

Institutes: Hirosaki University, Dept. of Urology, Hirosaki, Japan

Summary and context
 G. Jenster, Rotterdam (NL)